Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Golimumab shows sustained efficacy for ankylosing spondylitis

Audrey Abella
14 Nov 2019

The efficacy of the monoclonal anti-TNF* antibody golimumab was maintained in patients with active ankylosing spondylitis (AS) through 1 year, according to the updated results of the GO-ALIVE** study.

“A consistent, high level of response was observed … [and] golimumab concentrations were maintained at a steady state in both treatment groups through 1 year,” said the researchers. These findings come on the heels of the initial results­, wherein the primary endpoint – ASAS20*** – and all controlled endpoints were achieved at week 16 and maintained through week 28. [J Rheumatol 2018;45:341-34]

As previously reported, 208 individuals with AS were randomized 1:1 to receive intravenous infusions of golimumab 2 mg/kg (weeks 0, 4, and every 8 weeks [Q8W] thereafter) or placebo (weeks 0, 4, and 12). Placebo recipients crossed over to golimumab at week 16 and continued to receive the study drug at week 20 and Q8W thereafter. The current efficacy assessment ran through week 52, while safety was monitored until week 60. [J Rheumatol 2019;46;1277-1283]

At week 52, ASAS20 was achieved by ~2/3 of golimumab and placebo crossover recipients (69.5 percent and 65.0 percent). More than half of participants in both golimumab and placebo crossover arms achieved ASAS40*** (56.2 percent and 51.5 percent) and BASDAI50# (56.2 percent and 55.3 percent), while almost a quarter achieved ASAS partial remission (24.8 percent and 24.3 percent).

Following crossover to golimumab at week 16, favourable responses were achieved as early as week 20 and remained steady through week 52, the researchers pointed out. “This rapid improvement may be … partially attributed to the placebo response occurring through week 16 in these patient-driven outcomes, with further improvement upon switching to golimumab.”

Mean changes in Bath Ankylosing Spondylitis Functional Index (BASFI) and AS Quality of Life index (ASQoL) scores from baseline to week 52 were similar between the golimumab and placebo crossover arms (-2.7 and -2.6 [BASFI]; -5.5 and -5.4 [ASQoL]).

About 55 percent of all golimumab recipients reported ≥1 adverse events (AE) through week 60, with 3.4 percent having ≥ 1 serious AE. There were only a few participants who discontinued treatment through 1 year.

“[O]ver 90 percent of patients completed study infusions through week 52 … Moreover, the safety events through 1 year … were consistent with other anti-TNF therapies in AS; [however,] it should be noted that this study was not powered to detect rare events,” said the researchers.

AS is potentially debilitating due to the reduced spinal mobility brought about by the progressive spinal stiffness, consequently leading to a substantial impairment in health-related quality of life. [Hip Pelvis 2017;29:211-222; Arthritis Rheum 2007;57:1050-1057] Current treatment recommendations include non-steroidal anti-inflammatory drugs (NSAIDs) and anti-TNF agents for cases that do not respond well to NSAIDs. [Arthritis Rheumatol 2016;68:282-298]

Taken together, the findings show that golimumab effectively reduced the signs and symptoms of AS among NSAID nonresponders with sustained response through 1 year, thereby reinforcing evidence reflecting the potential of golimumab in this setting, concluded the researchers.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.